Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Oncology dominates the growth outlook for pharma; four of the eight drugs expected to add $1bn or more in new sales next year are for cancer, according to the Vantage…
Evaluate Ltd., the leading provider of commercial data to the life sciences industry, is pleased to announce the appointment of Martyn Hindley as Chief Financial Officer,…
Breakthrough offering combines the power of machine learning with the transparency of Evaluate’s renowned analytical approach for the most accurate analysis of drug…
Vantage releases its half-year analysis of sector performance: Pharma, Biotech and Medtech Half-Year Review 2018
Eleventh annual EvaluatePharma World Preview 2018, Outlook to 2024 report launches at BIO 2018.
Annual “EvaluatePharma Orphan Drug 2018 Report” sees Orphan drugs capture a fifth of worldwide prescription sales by 2024 as sales grow to $262bn.
EP Vantage releases its annual analysis of sector performance: Pharma, Biotech and Medtech 2017 in Review.
EP Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2018.
EvaluateMedTech Report Launches in Conjunction with The MedTech Conference.
EP Vantage Releases Half-Year Reviews of Pharma & Biotech and Medtech Performance.
Latest growth forecasts show optimism surrounding new therapies coming to market counterbalanced by more stringent pricing policy enforcement.
New Case Studies Highlight Niche Patient Population Identification and Analysis for Enhanced Portfolio Decision-making Using Evaluate’s Epi Analyzer